Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

NCT01990209 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT01990209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01990209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2014
Completion date
May 1, 2021
Enrollment
71 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer